The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

Kai-Michael Beeh,1 Eric Derom,2 José Echave-Sustaeta,3 Lars Grönke,4 Alan Hamilton,5 Dongmei Zhai,6 Leif Bjermer71Insaf GmbH Institut für Atemwegsforschung, Wiesbaden, Germany; 2Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium; 3Servicio de Neum...

Full description

Bibliographic Details
Main Authors: Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L
Format: Article
Language:English
Published: Dove Medical Press 2016-02-01
Series:International Journal of COPD
Subjects:
COPD
maintenance treatment
lung function
tiotropium
olodaterol
inhaled corticosteroid
Online Access:https://www.dovepress.com/the-lung-function-profile-of-once-daily-tiotropium-and-olodaterol-via--peer-reviewed-article-COPD

Internet

https://www.dovepress.com/the-lung-function-profile-of-once-daily-tiotropium-and-olodaterol-via--peer-reviewed-article-COPD

Similar Items